Current role of neoadjuvant and adjuvant systemic therapy for high-risk localized prostate cancer

Current Opinion in Urology

Volumn 23, Issue 4, 2013, Pages 366-371

  Dorff, Tanya B ^a   Glode, L Michael ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

androgen deprivation therapy; chemotherapy; high risk localized prostate cancer

Indexed keywords

ABIRATERONE; ANDROGEN; ANDROSTANOLONE; ANDROSTENEDIOL; ANDROSTENEDIONE; DOCETAXEL; PRASTERONE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ANDROGEN DEPRIVATION THERAPY; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER LOCALIZATION; CANCER MORTALITY; CANCER RECURRENCE; CLINICAL TRIAL (TOPIC); DRUG COST; EXTERNAL BEAM RADIOTHERAPY; HIGH RISK PATIENT; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REVIEW; SYSTEMIC THERAPY; TREATMENT DURATION;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; CHEMORADIOTHERAPY; HUMANS; KALLIKREINS; MALE; NEOADJUVANT THERAPY; NEOPLASMS, HORMONE-DEPENDENT; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84880137043     PISSN: 09630643     EISSN: 14736586     Source Type: Journal    
DOI: 10.1097/MOU.0b013e328361d467     Document Type: Review

References (43)

1. Pilepich MV, Caplan R, Byhardt RW, et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group protocol 85-31. J Clin Oncol 1997; 15:1013-1021.
2. Hanks GE, Pajak TF, Porter A, et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group protocol 92-02. J Clin Oncol 2003; 21:3972-3978.
3. Keating NL, O'Malley J, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006; 27:4448-4456.
4. Tsai HK, D'Amico AV, Sadetsky N, et al. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. Ann Oncol 2007; 99:1516-1524.
5. Gilbert SM, Kuo YF, Shahinian VB. Prevalent and incident use of androgen deprivation therapy among men with prostate cancer in the United States. Urol Oncol Semin Orig Investig 2011; 29:647-653.
6. Krahn M, Bremner KE, Tomlinson G, et al. Androgen deprivation therapy in prostate cancer: are rising concerns leading to falling use? BJU Int 2011; 108:1588-1596.
7. Nguyen PL, Je Y, Schultz FAB, et al. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer. JAMA 2011; 306:2359-2366.
8. Takaha N, Okihara K, Kamoi K, et al. Optimal duration of androgen deprivation in combination with radiation therapy for Japanese men with high-risk prostate cancer. Urologia Int 2011; 87:28-34.
9. Zapatero A, Garcia-Vicente F, Martin de Vidales C, et al. Long-term results after high-dose radiotherapy and adjuvant hormones in prostate cancer: how curable is high-risk disease? Int J Radiat Oncol Biol Phys 2011; 81:1279-1285.
10. Zelefsky MJ, Pei X, Chou JF, et al. Dose escalation for prostate cancer radiotherapy: predictors of long-term biochemical tumor control and distant metastases-free survival outcomes. Eur Urol 2011; 60:1133-1139.
11. Zeitman AL, Prince EA, Nakfoor BM, Park JJ. Androgen deprivation and radiation therapy: sequencing studies using the shionogi in vivo tumor system. Int J Rad Oncol Biol Phys 1997; 38:1067-1070.
12. Langenhuijsen JF, van Lin EN, Hoffman AL, et al. Neoadjuvant androgen deprivation for prostate volume reduction: the optimal duration in prostate cancer radiotherapy. Urol Oncol Semin Orig Invest 2011; 29:52-57.
13. Denham JW, Steigler A, Lamb DS, et al. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol 2011; 12:451-459.
14. Alexander AS, Mydin A, Jones SO, et al. Extreme-risk prostate adenocarci-noma presenting with prostate-specific antigen (PSA) >40ng/mL: prognostic significance of the preradiation PSA nadir. Int J Radiation Oncol Biol Phys 2011; 81:e713-e719.
15. Malik R, Jani AB, Liauw SL. Prostate-specific antigen halving time while on neoadjuvant androgen deprivation therapy is associated with biochemical control in men treated with radiation therapy for localized prostate cancer. Int J Rad Onc Biol Physics 2011; 79:1022-1028.
16. Alonzi R, Padhani AR, Taylor NJ, et al. Antivascular effects of neoadjuvant androgen deprivation for prostate cancer: an in vivo human study using susceptibility and relaxivity dynamic MRI. Int J Rad Onc Biol Physics 2011; 80:721-727.
17. Berglund RK, Tangen CM, Powell IJ, et al. Ten-year follow-up of neoadjuvant therapy with goserelin acetate and flutamide before radical prostatectomy for clinical T3 and T4 prostate cancer: update on Southwest Oncology Group Study 9109. Urology 2012; 79:633-637.
18. Taplin ME, Montgomer RB, Logothetis C, et al. Effect of neoadjuvant abir aterone acetate plus leuprolide on PSA, pathological complete response (pCR), and near pCR in localized high-risk prostate cancer: results of a randomized phase II study. J Clin Oncol 2012; 30 (Suppl):4521.
19. Ross RW, Galsky MD, Febbo P, et al. Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer. Cancer 2012; 118:4777-4784.
20. Narita S, Tsuchiya N, Kumazawa T, et al. Short term clinicopathological outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade, followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy in Japanese patients with high-risk localized prostate cancer. World J Surg Onc 2012; 10:1.
21. Womble PR, VanVeldhuizen PJ, Nisbet AA, et al. A phase II clinical trial of neoadjuvant ketoconazole and docetaxel chemotherapy before radical prostatectomy in high risk patients. J Urol 2011; 186:882-887.
22. Kim WY, Whang YE, Pruthi RS, et al. Neoadjuvant docetaxel/estramustine prior to radical prostatectomy or external beam radiotherapy in high risk localized prostate cancer: a phase II trial. Urol Oncol 2011; 29:608-613.
23. Fujimoto N, Kubo T, Shinsaka H, et al. Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer. BMC Urol 2011; 11:7.
24. Arai S, Miyashiro Y, Shibata Y, et al. Effect of castration monotherapy on the levels of adrenal androgens in cancerous prostatic tissues. Steroids 2011; 76:301-308.
25. Lehmusvaara S, Erkkila T, Urbanucci A, et al. Chemical castration and antiandrogens induce differential gene expression in prostate cancer. J Pathol 2012; 227:336-345.
26. Fuzio P, Ditonno P, Lucarelli G, et al. Androgen deprivation therapy affects Bcl-2 expression in human prostate cancer. Int J Oncol 2011; 39:1233-1242.
27. Tzelepi V, Efstathiou E, Wen S, et al. Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment. J Clin Oncol 2011; 29:2574-2581.
28. Sorrentino C, Musiani P, Pompa P, et al. Androgen deprivation boosts prostatic infiltration of cytotoxic and regulatory T lymphocytes and has no effect on disease-free survival in prostate cancer patients. Clin Cancer Res 2011; 17:1571-1581.
29. Messing EM, Manola J, Yao J, et al. Immediate versus deferred androgren deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006; 7:472-479.
30. Flaig TW, Tangen CM, Hussain MHA, et al. Randomization reveals unexpected leukemias in Southwest Oncology Group prostate cancer trial. J Clin Oncol 2007; 26:1532-1536.
31. Dorff TB, Flaig TW, Tangen CM, et al. Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study. J Clin Oncol 2011; 29:2040-2045.
32. Epstein JI, Pizov GT, Walsh PC. Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer 1993; 71:3582-3591.
33. Roehl KA, Ramos CG, Anenor JA, et al. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3478 consecutive patients: long-term results. J Urol 2004; 172:910-914.
34. Partin AW, Lee BR, Carmichael M, et al. Radical prostatectomy for high grade disease: a reevaluation 1994. J Urol 1994; 152:1843-1849.
35. Nguyen CT, Reuther AM, Stephenson AJ, et al. The specific definition of high risk prostate cancer has minimal impact on biochemical relapse-free survival. J Urol 2009; 181:75-80.
36. Schubert M, Joniau S, Gontero P, et al. The role of adjuvant hormonal treatment after surgery for localized high-risk prostate cancer: results of a matched multiinstitutional analysis. Adv Urol 2012 [Epub ahead of print].
37. Stenmark MH, Blas K, Halverson S, et al. Continued benefit to androgen deprivation therapy for prostate cancer patients treated with dose-escalated radiation therapy across multiple definitions of high-risk disease. Int J Rad Oncol Biol Physics 2011; 81:335-344.
38. Siddiqui SA, Boorjian SA, Blute ML, et al. Impact of adjuvant androgen deprivation therapy after radical prostatectomy on the survival of patients with pathological T3b prostate cancer. BJU Internatl 2011; 107:383-389.
39. Daly PE, Dunne MT, O'Shea CM, et al. The effect of short-term neoadjuvant androgen deprivation on erectile function in patients treated with external beam radiotherapy for localized prostate cancer: an analysis of the 4-versus 8-month randomized trial (Irish Clinical Oncology Research Group 97-101. Radiother Oncol 2012; 104:96-102.
40. DiBiase SJ, Hussain A, Kataria R, et al. Long-term results of prospective, phase II study of long-term androgen ablation, pelvic radiotherapy, brachyther-apy boost, and adjuvant docetaxel in patients with high-risk prostate cancer. Int J Rad Oncol Biol Phys 2011; 81:732-736.
41. Resnick MJ, Koyama T, Fan K-H, et al. Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med 2013; 368:436-445.
42. Saini A, Berruti A, Cracco C, et al. Psychological distress in men with prostate cancer receiving adjuvant androgen deprivation therapy. Urol Oncol Semin Orig Invest 2011 [Epub ahead of print].
43. Sadetsky N, Greene K, Coooperberg MR, et al. Impact of androgen deprivation of physical well being in patients with prostate cancer. Cancer 2011; 117:4406-4413.